IL278618B2 - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
IL278618B2
IL278618B2 IL278618A IL27861820A IL278618B2 IL 278618 B2 IL278618 B2 IL 278618B2 IL 278618 A IL278618 A IL 278618A IL 27861820 A IL27861820 A IL 27861820A IL 278618 B2 IL278618 B2 IL 278618B2
Authority
IL
Israel
Prior art keywords
cancer
treatment
Prior art date
Application number
IL278618A
Other languages
English (en)
Hebrew (he)
Other versions
IL278618B1 (en
IL278618A (enExample
Original Assignee
Medimmune Ltd
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Innate Pharma filed Critical Medimmune Ltd
Publication of IL278618A publication Critical patent/IL278618A/en
Publication of IL278618B1 publication Critical patent/IL278618B1/en
Publication of IL278618B2 publication Critical patent/IL278618B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL278618A 2018-05-15 2020-11-10 Cancer treatment IL278618B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671521P 2018-05-15 2018-05-15
PCT/EP2019/062305 WO2019219658A1 (en) 2018-05-15 2019-05-14 Treatment of cancer

Publications (3)

Publication Number Publication Date
IL278618A IL278618A (enExample) 2021-01-31
IL278618B1 IL278618B1 (en) 2025-07-01
IL278618B2 true IL278618B2 (en) 2025-11-01

Family

ID=66752041

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278618A IL278618B2 (en) 2018-05-15 2020-11-10 Cancer treatment

Country Status (13)

Country Link
US (1) US12209126B2 (enExample)
EP (1) EP3793607A1 (enExample)
JP (2) JP7531404B2 (enExample)
KR (1) KR102885515B1 (enExample)
CN (1) CN112203691A (enExample)
AU (2) AU2019270277B9 (enExample)
CA (1) CA3099820A1 (enExample)
EA (1) EA202092696A1 (enExample)
IL (1) IL278618B2 (enExample)
MA (1) MA52627A (enExample)
SG (1) SG11202011117VA (enExample)
TW (1) TW202011989A (enExample)
WO (1) WO2019219658A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3193929T3 (da) 2014-09-16 2019-08-19 Innate Pharma Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer
KR20200133233A (ko) 2018-03-13 2020-11-26 이나뜨 파르마 두부경부암의 치료
CN113583127A (zh) * 2020-04-30 2021-11-02 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
IL297412A (en) * 2020-05-04 2022-12-01 Immunorizon Ltd Precursor tri-specific antibody constructs and methods of use thereof
EP4150058A4 (en) * 2020-05-13 2024-06-19 Nanjing Legend Biotech Co., Ltd. COMPOSITIONS AND METHODS FOR REDUCING HOST REJECTION OF ALLOGENIC CELLS USING MONKEY ICP47 AND VARIANTS THEREOF
WO2023284874A1 (zh) * 2021-07-16 2023-01-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
CA3233771A1 (en) * 2021-10-04 2023-04-13 Les Laboratoires Servier Cancer therapy targeting nkg2a
US20240415889A1 (en) * 2021-12-14 2024-12-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to cd94/nkg2a heterodimer polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017125532A1 (en) * 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
US20170253658A1 (en) * 2014-08-28 2017-09-07 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO2003101485A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
EP3026063A1 (en) 2004-12-28 2016-06-01 Innate Pharma S.A. Monoclonal antibodies against nkg2a
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
MX2008015830A (es) 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
BRPI0908508A2 (pt) 2008-01-24 2016-03-22 Novo Nordisk As anticorpo monoclonal nkg2a anti-humano humanizado
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
CN103635487B (zh) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞
DK3193929T3 (da) 2014-09-16 2019-08-19 Innate Pharma Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer
CN113929782B (zh) 2014-09-16 2024-06-21 依奈特制药公司 对淋巴细胞中抑制途径的中和
RU2721271C2 (ru) 2014-10-23 2020-05-18 Иннейт Фарма Лечение раковых заболеваний с применением анти-nkg2a средств
KR20200133233A (ko) 2018-03-13 2020-11-26 이나뜨 파르마 두부경부암의 치료

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170253658A1 (en) * 2014-08-28 2017-09-07 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017125532A1 (en) * 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes

Also Published As

Publication number Publication date
US20210253694A1 (en) 2021-08-19
EP3793607A1 (en) 2021-03-24
IL278618B1 (en) 2025-07-01
WO2019219658A1 (en) 2019-11-21
JP7531404B2 (ja) 2024-08-09
SG11202011117VA (en) 2020-12-30
KR102885515B1 (ko) 2025-11-12
AU2019270277B9 (en) 2024-12-05
CN112203691A (zh) 2021-01-08
AU2019270277A1 (en) 2021-01-07
US12209126B2 (en) 2025-01-28
JP2024102055A (ja) 2024-07-30
AU2025200275A1 (en) 2025-01-30
MA52627A (fr) 2021-03-24
CA3099820A1 (en) 2019-11-21
AU2019270277B2 (en) 2024-11-21
EA202092696A1 (ru) 2021-04-05
IL278618A (enExample) 2021-01-31
TW202011989A (zh) 2020-04-01
JP2021523170A (ja) 2021-09-02
KR20210010486A (ko) 2021-01-27

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
EP3630089A4 (en) PROCEDURE FOR CANCER THERAPY
IL267795A (en) Combined treatment for cancer
IL278618B2 (en) Cancer treatment
GB201804514D0 (en) Treatment of pyroptosis
SMT202100245T1 (it) Trattamento combinato del cancro
IL277981A (en) Cancer treatment methods
IL323981A (en) Cancer treatment methods
SG11202010793UA (en) Methods of treating cancer
ZA201908539B (en) Method of treatment of cancer
IL263835A (en) Exosome-guided treatment of cancer
IL263905A (en) Combined cancer treatment
IL266993A (en) Combined therapy for cancer treatment
GB201804515D0 (en) Treatment of necroptosis
IL267613A (en) Pancreatic cancer treatment
SG11202005163PA (en) Methods of treating cancer
IL274748A (en) Improved cancer treatment
IL269123A (en) Methods of treating cancer
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
GB201918815D0 (en) Treatment of cancer
GB201820975D0 (en) Methods of cancer treatment
GB201820098D0 (en) Methods of cancer treatment
GB201819920D0 (en) Cancer treatment
IL253642A0 (en) Combined treatment for cancer
HK40050796A (en) Treatment of cancer